Goloubeva, Olga | University of Maryland School of Medicine

Academic Title:

Professor

Primary Appointment:

Epidemiology & Public Health

Administrative Title:

Interim Director for the UMGCCC Biostatistics Shared Service

Email:

ogoloubeva@som.umaryland.edu

Location:

Howard Hall, 111

Phone (Primary):

(410) 706-8502

Phone (Secondary):

(410) 706-8505

Fax:

(410) 706-8548

Download CV

Education and Training

M.Sc., Fellowship and Assistantship Dalhousie University, Halifax, Nova Scotia, Canada
Ph.D., confirmed and approved by University of Toronto, Toronto, Canada by Comparative Education Service of Canada
Ph.D., State Technical University, Moscow, Russia, Engineering: Optimization of industrial processes
M.Sc., B.S., National University of Science and Technology, Moscow, Russia, Engineering: Development of advanced materials and technologies

Biosketch

Dr. Goloubeva's work focuses on the design and statistical analysis of pre-clinical studies and Phase I-III clinical trials; evaluation of diagnostic tests, biomarkers, and their combination; prognostic models of cancer and other diseases; longitudinal and hierarchical data modeling; and integration of data from proteomics and genomics into modeling of cancer patients' survival experience. She has been using a wide variety of biostatistical methods for quantitative cancer research augmented by knowledge of the principles of cancer biology and clinical management of cancer. Her special interest lies in designs and biomarker discovery studies including the analysis of high-dimensionality data sets and longitudinal modeling of marker changes in response to therapy. She developed interest in using population-based cancer registries linked SEER-Medicare database and NCDB to study treatment of cancer, outcomes, and cost. The ongoing collaboration in research of many different cancers and diseases is reflected in her more than130 peer-reviewed publications since 2000.

Research/Clinical Keywords

Clinical trial design, population-based databases, bio-statistics

Highlighted Publications

Aaron P. Rapoport, Edward A. Stadtmauer, Gwendolyn K. Binder-Scholl, Olga Goloubeva, Dan T. Vogl, Simon Lacey, Ashraf Z. Badros, Alfred Garfall, BrendanWeiss, Jeffre Finklestein, Irina Kulikovskaya, Sanjoy K. Sinha, ShariKronsberg, Minnal Gupta, Sarah Bond, Luca Melchiori, Joanna E. Brewer, AlanD. Bennett, Andrew B. Gerry, Nick J. Pumphrey, Daniel Williams, Helen K. Tayton-Martin, Lilliam Ribeiro, Tom Holdich, Saul Yanovich, Nancy Hardy, Jean Yared,Naseem Kerr, Sunita Philip, Sandra Westphal, Don L. Siegel, Bruce L. Levine, Bent K. Jakobsen, Michael Kalos, and Carl H. June. NY-ESO-1 specific engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Medicine. 2015 Aug; 21(8): 914-21.(Data analysis, manuscript writing).

McCusker MG, Mehra R, Amr S, Taylor RJ, Cullen KJ, Goloubeva OG. Comparison of efficacy and toxicity of chemoradiation regimens for head and neck squamous cell carcinoma primary treatment. Head Neck. 2022 Mar;44(3):749-759. doi: 10.1002/hed.26965. Epub 2021 Dec 20. PMID: 34931731 (Study design, data analysis, manuscript writing).

Oates TW, Guy V, Ni K, Ji C, Saito H, Shiau H, Shah R, Williams MA, Blasi G, Goloubeva O. Meta-regression analysis of study heterogeneity for systematic outcomes after periodontal therapy. JDR Clin Trans Res. 2022 Jan 17:23800844211070467. doi: 10.1177/23800844211070467. Online ahead of print. PMID: 35037489. (Analysis, manuscript writing).

Additional Publication Citations

Zandberg DP, Liu S, Goloubeva O, Ord R, Strome SE, Suntharalingam M, Taylor R, Morales RE, Wolf JS, Zimrin A, Schumaker LM, Cullen KJ. Orapharungeal cancer (OPC) drives racial outcome disparities in squamous cell carcinoma of the head and neck (HNSCC): Ten year experience at the University of Maryland Greenebaum Cancer Center (UMGCC). Head and Neck. 2016 Apr; 38(4): 564-72. (Data analysis, manuscript writing).

Albarmawi H, Cullen KJ, Mehra R, Onukwugha E, Goloubeva O. Cost-effectiveness of concurrent radiation with cetuximab or chemotherapy in older patients with oropharyngeal cancer. J Comp Eff Res. 2022 Jun;11(8):595-607. doi: 10.2217/cer-2021-0209. Epub 2022 May 11.PMID: 35543585.

Lutfi F, Goloubeva O, Kowatli A, Gryaznov A, Kim DW, Dureja R, Margiotta P, Matsumoto LR, Bukhari A, Ahmed N, Mushtaq MU, Law JY, Lee ST, Kocoglu MH, Atanackovic D, Yared JA, Hardy NM, McGuirk JP, Rapoport AP, Chen W, Dahiya S. Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by ¹⁸F-FDG PET/CT Imaging Following CAR-T Therapy. Clin Lymphoma Myeloma Leuk. 2023 Oct; 23(10):757-763. doi: 10.1016/j.clml.2023.06.005. Epub 2023 Jun 19. PMID: 37453865.

Alkhaldi H, Goloubeva O, Rapoport AP, Dahiya S, Pang Y, Ali MM, Hardy NM, Mohindra P, Bukhari A, Lutfi F, Sanchez-Petitto G, Molitoris J, Samanta S, Li X, Toth T, Landau M, Hodges S, Nishioka J, Ruehle K, Ridge L, Gahres N, Kocoglu MH, Atanackovic D, Malinou JN, Yared JA. Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center Experience. Transplant Proc. 2023 Jan-Feb;55(1): 214-224. doi: 10.1016/j.transproceed. 2022. 10.061. Epub 2023 Jan 11. PMID: 36635141.

Sanchez-Petitto G, Goloubeva OG, Masur J, Childress J, Iqbal T, An M, Muhammad S, Lawson J, Li G, Barr B, Emadi A, Law JY, Lee ST, Duong VH, Baer MR, Niyongere S. Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease. Leuk Res. 2024 Feb 20;138:107456. doi: 10.1016/j.leukres.2024.107456. PMID: 38442593.

Research Interests

Dr. Goloubeva's work focuses on the design and statistical analysis of preclinical studies and Phase I-III clinical trials; evaluation of diagnostic tests, biomarkers, and their combination; and prognostic models of cancer. Her main research interests include longitudinal and hierarchical data modeling; applied biostatistics; and integration of data from proteomics and genomics into modeling of cancer patients' survival experience.

Grants and Contracts

MPower
Goloubeva (PI)
07/01/15-06/30/16
Ethnic disparities in health care utilization among African American, Hispanic and Causian survivors of multiple myeloma and head and neck cancer
Role: PI

MPower
MacPherson (PI)
7/1/2015-6/30/2016
Behavioral treatment for low-income depressed smokers in the community
Role: Co-PI

BX002184
Baer (PI)
10/01/14–09/30/18
Veterans Administration
Inhibition of Pim Kinases in Acute Myeloid Leukemia
Role: Co-investigator

VA Merit
Passaniti (PI)
10/1/15-09/30/16
BX002205-01
Transcriptional Regulation of Tumor Growth
Role: Co-Investigator

5R01CA16300-03
Perrotti (PI)
02/01/14–01/31/18
NCI
Role of MicroRNAs in the Regulation of Chronic Myeloid Leukemia Stem Cell Survival and Self Renewal
Role: Co-Investigator

204113
Dorgan (PI)
01/01/15–12/31/16
American Institute for Cancer Research
Prospective Study of Diet in Youth and Adult Breast Density
The objective of this study is identify dietary factors in youth that influence breast density.
Role: Co-investigator

P30CA134274-01
Cullen (PI)
08/01/08–07/30/20
National Cancer Institute (NCI)
University of Maryland Cancer Center Support Grant
The goal of this grant is to provide infrastructure support to the University of Maryland UMGCC.
Role: Co-investigator

R21CA187974
Rassool (PI)
07/01/15-06/30/17
Mechanisms for sensitivity to PARP inhibitors in cancers involving ALT NHEJ
Role: Co-investigator

Professional Activity

Local and National Service

Reviewer, Cancer, Cancer Research, 2005-Present
Reviewer, Cancer Chemotherapy and Pharmacology, 2011-Present
Reviewer, Journal of Cancer Education, 2016-Present
Statistical Consultant, NIH/NIA, 2008-2010
Member, DSM Board for NIH/NIA Phase II trial (Alzheimer's disease), Baltimore, MD, 2010-Present
Statistical Consultant, Alper Biotech, LLC, Rockville, MD, 2010-2011
Statistical Consultant, BioMarker Strategies Company, Baltimore, MD, 2010-2012
Statistical Consultant, SNBL Clinical Pharmacol Center, Baltimore, MD, 2010-2012
Member, DSM Board for NIH/NIA trial in Phase I study (Alzheimer's disease), Baltimore, MD, 2012-Present
Member, NIH/NIA IRP Scientific Review Committee, 2012-Present
Reviewer and Member of a Panel, SBIR/STTR applications, NIH/NIDCR, Bethesda, MD, 2015

International Service